GLP-1 RECEPTOR AGONIST AND DPP-4 INHIBITOR COMBINATION THERAPYThe present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.KLEIN, THOMASGREMPLER, ROLFMARK, MICHAEL
are elevated in a glucoxse dependent manner.3,4 Increased insulin levels improve glucose uptake by peripheral tissues; the combination of increased insulin and decreased glucagon reduces hepatic glucose output.5 The incretins are rapidly inactivated by the dipeptidyl peptidase 4 (DPP-4) enzyme.??
GLP-1(7-36)酰胺在生物体内代谢迅速,DPP-IV(dipeptidyl peptidase IV)会使其失去N-末端的两个氨基酸变为 GLP-1(9-36)酰胺,GLP-1(7-37)变为 GLP-1(9-37)后会失去活性。有报告指出,体外实验中,在犬的血浆中 GLP-1(7-36)酰胺的半衰期是为 61±9 分,GLP-1(7-37)为 132±16 分。因此 GLP-1 的...
Nonalcoholic steatohepatitis (NASH), as a severe form of nonalcoholic fatty liver disease (NAFLD), is characterized by liver steatosis, inflammation, hepatocellular injury and different degrees of fibrosis. The pathogenesis of NASH is complex and multifa
2.Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.[J].Hellqvist A;Scheen AJ;Charpentier G;Gause Nilsson I;Ostgren CJ,Diabetes - Metabolism: Research & Reviews..2010,第7期 ...
GLP-1- based treatments for T2DM, such as GLP-1 receptor agonists, dual and triple agonists that activate GLP-1R, GIPR, and glucagon receptors, and dipeptidyl peptidase-4 (DPP-4) inhibitors have been reviewed here. In addition, we discuss the increase in the endogenous secretion of this hor...
Education Lab | CME | The incretin-based therapies, including GLP-1 receptor agonists and DPP-4 inhibitors, have been shown to offer a number of benefits over other treatments for type 2 diabetes, including reduction of cardiovascular risk, weight reduct
[37] Eng, C., Kramer, C.K., Zinman, B., Retnakaran, R. 2014. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 384:22...
Dipeptidyl peptidase-4 (DPP-4) inhibitors (from now on DPP-4i) are newly available drugs approved for the treatment of type 2 diabetes mellitus, either as monotherapy or in combination with oral agents (metformin, glitazones, and/or sulphonylureas) and insulin (Drucker and Nauck, 2006). ...
kidney have been proposed. Here, we review the role of GLP-1 and the actions of associated therapies on glucose metabolism, the gut–renal axis, classical renal risk factors, and renal end points in randomized controlled trials of GLP-1 receptor agonists and DPP-4 inhibitors in patients with...